GWPH GW Pharmaceuticals Plc

-1.38  -1%
Previous Close 150.49
Open 150.45
Price To Book 11.11
Market Cap 4554382639
Shares 30,542,958
Volume 147,002
Short Ratio
Av. Daily Volume 487,768

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 open-label trial to commence 1Q 2019.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016. Part A nearing completion, unlikely to continue through to Part B.
Infantile spasms (IS)
Phase 2 trial did not meet endpoint
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Cancer pain
Phase 2 data released February 21, 2018 - primary endpoint not met.
GWP42006 (CBDV)
Phase 2 data released September 2015. Currently evaluating next steps
Approval announced June 25, 2018.
Dravet Syndrome and Lennox-Gastaut syndrome
Phase 3 data due 2Q 2019.
Tuberous Sclerosis Complex
Phase 3 trial planned for 2H 2019.
Spasticity due multiple sclerosis
GWP42006 (CBDV)

Latest News

  1. Why Marijuana ETFs are on a High in 2019
  2. 3 Very Popular Marijuana Stocks You Couldn't Pay Me to Buy
  3. 4 Best Marijuana Stocks to Play the Green Rush
  4. 4 Marijuana Stocks Bubbling with Excitement on Wednesday (2/13/19)
  5. Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks?
  6. Biotech and Cannabis Stocks That Are Emerging
  7. GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know
  8. Green Growth Brands Ended in the Red Last Week
  9. Why Marijuana Stock GW Pharmaceuticals Soared 46.6% in January
  10. 3 Legal Marijuana States Are Banning CBD Edibles. Here's Why.
  11. Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
  12. 4 Marijuana Stocks Looking To Pick Up Speed This Month
  13. 3 Brand-Name Marijuana Stocks Short-Sellers Are Liable to Target
  14. GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019
  15. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  16. Top Cannabis and Biotech Stocks To Watch
  17. The 13 Largest Pot Stocks by Market Cap
  18. Pot Stocks are on a High: Play These Marijuana ETFs
  19. Biotech on the Brink of Breaking Out
  20. 420 Investor: GW Pharma Investors May Have To Wait Out Short-Term Volatility